We have reported previously on two truncations of apolipoprotein B (apo B40 and apo B-89) in a kindred with hypobetalipoproteinemia. Premature stop codons were found to be responsible for both apo B40 and apo B-89, but the physiologic mechanisms accounting for the reduced plasma concentrations of these proteins have not been determined in vivo. This study investigates the metabolism of apo B-89 in two subjects heterozygous for apo B-89/apo B-100 and in one apo B40/apo B-89 compound heterozygote. In both heterozygotes total apo B concentration is -30% of normal and apo B-89 is present in lower concentrations in plasma than apo B-100. After the administration of [1-3Cqleucine as a primed constant infusion over 8 h, 'C enrichments of plasma leucine as well as enrichments of VLDL-, IDL-, and LDL-apo B-89 leucine and VLDL-, IDL-, and LDL-apo B-100 leucine were measured over 110 h. Enrichment values were subsequently converted to tracer/tracee ratios and a multicompartmental model was used to estimate metabolic parameters. In both apo B-89/apo B-100 heterozygotes apo B-89 and apo B-100 were produced at similar rates. Respective transport rates ofapo B-89 and apo B-100 for subject 1 were 2.13±0.18 and 2.56±0.13 mg -kg-' -d-1, and for subject 2, 6.59±0.18 and 8.23±0.39 mg kg-'d -. However, fractional catabolic rates of VLDL, IDL, and LDL particles containing apo B-89 were 1.4-3 times higher than the rates for corresponding apo B-100-containing particles. Metabolic parameters of apo B-89 in the apo B40/apo B-89 compound heterozygote compared favorably with those established for apo B-89 in apo B-89/apo B-100 heterozygotes. Thus, the enhanced catabolism of VLDL, IDL, and LDL particles containing the truncated apolipoprotein is responsible for the relatively low levels of apo B-89 seen in these subjects. (J. Clin. Invest. 1992.89:1931-1937 Key words: in vivo kinetics -lipoprotein metabolism -multicompartmental model * truncated apolipoprotein B
Introduction Apolipoprotein B, a major protein associated with several lipoproteins in plasma, normally exists in two forms, apo B-100 and apo B-48. In humans, apo B-100, consisting of4536 amino acid residues, is synthesized in liver and is present in VLDL, IDL, and LDL, and apo B-48, consisting of 2152 residues (the NH2-terminus 48% of apo B-100), is found in chylomicrons and chylomicron remnants (1) . In addition, several unusual inherited truncations of apo B have been described in subjects with hypobetalipoproteinemia (1) (2) (3) (4) (5) . We have reported previously on a kindred with hypobetalipoproteinemia and two different truncations of apolipoprotein B (apo B): apo B-40 and apo B-89 (4, 5) . All simple heterozygous (apo B-89/apo B-100 or apo B-40/apo B-100) and compound heterozygous (apo B-40/apo B-89) members of this kindred have plasma cholesterol levels below the 10th and 5th percentiles, respectively. In apo B-89/apo B-100 heterozygotes total apo B concentrations are -30% of normal and apo B-89 is present at lower concentrations than apo B-l00 in all classes of apo B-containing lipoproteins. Mutations of the apo B gene producing two different premature stop codons are responsible for the apo B-89 and apo B-40 truncations (5) , but the physiologic mechanisms accounting for the reduced plasma concentrations of either apo B-40 or apo B-89 containing lipoproteins have not been de- fined. While apo B-40 is found primarily in the HDL fraction, the density distribution of apo B-89 resembles that of apo B-100 (4) . In apo B-89/apo B-100 heterozygotes the two apolipoproteins are known to exist on distinct particles, e.g., apo B-100 LDL and apo B-89 LDL (4, 6) . The fact that both apo B-89 and apo B-100 are found in the VLDL, IDL, and LDL density classes implies that both proteins are metabolized via similar pathways. Thus, the low levels of apo B-89 containing lipoproteins in these subjects are probably due to quantitative differences in their production (transport), conversion, or removal rates. This communication addresses the metabolism of VLDL, IDL, and LDL-apo B-89 in three affected individuals. Apo B metabolism was studied in two apo B-89/apo B-100 heterozygotes and in one apo B40/apo B-89 compound heterozygote using [1-'3C] leucine as the endogenously incorporated tracer. Metabolic parameters for apo B-89 and apo B-100 were estimated by multicompartmental modeling. The data indicate that apo B-89 and apo B-100 are produced at approximately equal rates, but apo B-89 containing particles are cleared more rapidly than their apo B-100 containing counterparts.
Methods
Subjects. Two heterozygotes (phenotype apo B-89/apo B-100) and one compound heterozygote (phenotype apo B-40/apo B-89) participated in the study after giving informed consent to the study protocol approved by the Human Studies Committee of Washington University, Study protocol. After fasting for 10 h, the subjects were admitted to the General Clinical Research Center at 6:00 P.M. An intravenous line was placed in the cubital vein ofeach arm. One line served for infusion of tracer and the other for blood sampling. At 8:00 P.M., a primed constant infusion was started, consisting of a bolus of [I-'3C]leucine (0.85 mg-kg-'), immediately followed by an 8-h constant infusion (at 0.85 mg-kg-' -hr-'). After the infusion was stopped the subjects remained fasting for another 8 h. 42 samples of plasma were drawn for assays ofamino acid enrichment (every 5 min during the first hour, and thereafter every 15 min, later, half hourly and hourly, and finally daily up to 110 h). 32 samples were drawn for VLDL-, IDL-, LDL-apo B leucine enrichment (every 10 min during the first hour, thereafter every 15 min, later, half-hourly, hourly, and finally every other day up to 110 h). Aliquots for determination of VLDL-, IDL-, and LDL-apo B pool sizes were drawn on five occasions during the course of the study. Plasma samples were processed immediately for isolation of lipoproteins, and aliquots were stored at -70'C until analysis.
Analytical methods
Isolation of lipoproteins: VLDL (d < 1.006 g a ml-'), IDL (d 1.006-1.0 19 g* ml-'), and LDL (d 1.0 19-1.063 g. ml-') were isolated by sequential ultracentrifugation (7) from 4 ml ofplasma using a rotor (50.4 TI; Beckman Instruments Inc., Palo Alto, CA).
Preparation ofapo B and isolation ofamino acids. Apo B-89 and apo B-100 were separated by polyacrylamide gel (3-6%) electrophoresis (8) at each time point from each lipoprotein fraction. Aliquots corresponding to 50-100 sg oftotal protein were applied per lane. Coomassie blue-stained bands of apo B-89 and apo B-100 were excised and hydrolysed in 12 N HCl for 16 h at 1 10C. Amino acids were isolated from the hydrolyzed gel pieces or from 0.3 ml plasma by cation exchange chromatography (9) .
Determination ofenrichment and calculation oftracer/tracee ratios.
Amino acids obtained from the plasma samples or from the hydrolyzed apo B gel bands were derivatized to n-acetyl-n-propanol-esters (9) . Enrichments were determined by gas chromatography-mass spectrometry using 1.5 m X 2.0 mm glass columns (Supelco Inc., Bellafonte, CA) packed with Amino Acid Packing (Alltech Associates Inc.) coupled to a Finnigan 3,300 quadropule mass spectrometer (10) . Isotope ratios were calculated from the observed ion current ratio (m/z 217/216) using a standard curve. Enrichments were calculated using the method of Cobelli et al. (1 1) . These values were subsequently converted to tracer/ tracee ratios (11) . Data in this format are analogous to specific radioactivity in radiotracer experiments.
Lipids and apo B. Plasma lipids were measured by commercially available tests (Wako Chemicals, Richmond, VA). Apo B levels were measured in VLDL, IDL, and LDL fractions by radioimmunoassay (12) and concentrations were confirmed by protein assays (13) . The values for apo B concentration measured with the radio immunoassay did not differ by more than 20% from values estimated from the protein assay, assuming that -40% of VLDL protein, 70% of IDL protein, and 90% of LDL protein represented apo B. Separation of apo B-89 from apo B-100 was achieved using 3-6% gradient SDS-polyacrylamide gels stained with Coomassie Blue. The protein bands corresponding to apo B-100 and apo B-89 were scanned by laser densitometry. Based on the assumption that both forms of apo B have the same chromogenicity, pool sizes of apo B-89 and apo B-100 were estimated by scanning three to five samples from different time points in each lipoprotein fraction and averaging ratios.
Modelfor apo B metabolism and calculation ofparameters. A simple multicompartmental model ( Fig. 1 ) was used to describe VLDL-, IDL-, and LDL-apo B leucine tracer/tracee ratios. In multicompartmental modeling, each compartment or pool represents a group of kinetically homogenous particles. In this study the CONSAM/SAAM ( 14) programs were used to fit the model to the observed tracer data. These programs use a weighted least squares approach to find the best possible fit. Metabolic parameters are subsequently derived from this best fit. This model is derived from previously published models (15) (16) (17) (18) and has been shown to describe apo B metabolism in four normolipidemic controls (19) who had total plasma cholesterol levels between the 5th and 50th percentile of age-, sex-, and race-matched controls. The model consists of a precursor compartment (compartment 1) and an intracellular delay compartment accounting for the synthesis ofapo B and the assembly of lipoproteins (compartment 2). Compartments 11 and 12 are used to account for the kinetics of the VLDL-apo B fraction and represent a minimal delipidation chain. Although only one VLDL sample is obtained at each time point, the two-compartment VLDL model is required to fit the VLDL tracer data. Compartment 11 represents a rapidly turning-over pool of VLDL particles and compartment 12 represents those VLDL particles that turn over more slowly. IDL-apo B (compartment 21) can be derived from either ofthe two VLDL compartments. LDL-apo B (compartment 31) is derived from the IDL fraction (compartment 21) or directly from VLDL compartment 11 through a shunt pathway. It is assumed that plasma leucine (compartment 1) is the source of the leucine that is incorporated into apo B. Plasma leucine tracer/tracee ratios were described by a triexponential function (described in detail in reference 19 ) that was used as a forcing function (20) in the model. It is further assumed that all apo B enters the plasma via compartment 11, thus transport rates through compartment 11 correspond to total apo B production. After fitting the model to the observed data, fractional catabolic rates (FCR)' and conversion rates were determined for apo B-89 and apo B-100. The FCR of VLDL-apo B is the weighted average (related to mass distribu- (19) is that a direct loss from compartment 1 (1I I -w out) was required to fit the observed tracer/tracee ratios of VLDL-apo B-89. Because of the low mass of IDL-apo B-89 in subject 2, tracer/tracee ratios could not be determined. To fit the model to this subject's apo B-89 data, it was assumed that all IDL was converted to LDL (thus, that the flux 21 -* out was zero). Furthermore, the FCR of the IDL compartment was free to adjust to provide the delay necessary to fit the LDL data. In this manuscript, the terms transport rate and production rate are used synonymously, as are FCR and fractional turnover rate. The term rate constant refers to the fractional turnover rate ofa pool related to a specific pathway (e.g., the fraction ofcompartment 11 that is converted to compartment 12 per day).
Results
Plasma concentrations of VLDL-, IDL-and LDL-apo B are presented for each subject in Table II Plasma leucine tracer/tracee ratios from a representative study (subject 1) are shown in Fig. 2 . After the bolus injection, the first sample at 5 min showed the peak tracer/tracee ratio followed by a rapid fall over the subsequent 30-min period. Thereafter, there was a relatively constant tracer/tracee ratio over 8 h due to the infusion, followed by a rapid fall when the infusion was stopped. The features of the plasma amino acid tracer/tracee ratio curves were very similar in all three subjects. Plasma leucine tracer/tracee ratio curves were fitted with triexponential functions (19) . These functions were subsequently used to define the forcing functions used in the multicompartmental model. Table III and the transport rates presented in Table IV can be calculated from the indicated rate constants as outlined in Methods. As calculated by the model, in subject 1 52% of VLDL-apo B-89 and 62% of VLDL-apo B-100 are in compartment 11, and the rest are in compartment 12; in subject 3 all VLDL-apo B-89 is in compartment 11. Figs. 3 and 4 show VLDL (A) and LDL (B) apo B leucine tracer/tracee ratios in the two apo B-89/apo B-100 heterozygotes (subjects 1 and 2). The symbols represent observed values while the lines represent the best fit ofthe multicompartmental model (Fig. 1) to the tracer data. As can be seen in Figs. 3 and 4 , there is good agreement between the model-derived fits and the observed apo B-89 and apo B-100 tracer data. Both the upward and the downward slopes of the tracer/tracee ratio curves for VLDL-apo B-89 were steeper than the analogous slopes for VLDL-apo B-100, and "plateau" values were reached earlier for the tracer/tracee ratios of the truncated protein (A). In the LDL fractions (B) the slopes of the tracer/tracee ratio curves were also steeper for the apo B-89 than for apo B-100-containing particles, and the tracer/tracee ratios in LDL-apo B-89 curves peaked at higher values than in the LDL-apo B-100 curves. Similar data were obtained for the IDL ofsubject 1 (not shown). The apo B tracer/tracee ratio curves in both apo B-89/ apo B-100 heterozygotes (Figs. 3 and 4) showed similar characteristics. The differences in upward and downward slopes in all three lipoprotein fractions, together with the earlier "plateau" in VLDL and the higher peaks in LDL, represent increased rates of appearance and disappearance of labeled apo B-89 compared with the labeled apo B-100 containing lipoproteins. A triexponential function was computer fitted (line) to observed plasma leucine tracer/tracee ratios (symbols) as described previously (19) . This function was subsequently used as a forcing function to describe the input of the tracer for the modeling process.
While the qualitative differences between the kinetics of apo B-89 and apo B-100 can be appreciated from the figures directly, multicompartmental modeling is necessary to quantify these differences (Fig. 1) . The lag time before the appear- Tables III and IV show metabolic parameters for apo B-89 and apo B-00 derived by multicompartmental modeling. Ofparticular interest are the parameters derived from the apo B-89/apo B-100 heterozygotes (subjects 1 and 2) in whom the metabolism of the truncated apo B can be compared with that of the normal apo B-100 under identical conditions. The FCR's of apo B-89 were 1.4-3 times higher than those of apo B-100 in all lipoprotein fractions. As described in Methods, the multicompartmental model used for the analysis of apo B tracer/tracee ratio data assumed that all apo B entered plasma as VLDL. VLDL-apo B transport rates therefore reflect total apo B production rates in each subject. In the apo B-89/apo B-l00 heterozygotes, VLDL-apo B transport rates were similar for apo B-89 and apo B-l00 (Table IV) . The increased FCR of apo B-89 reflects an enhanced irreversible loss of particles from each lipoprotein fraction rather than an increased conversion of VLDL to LDL. Thus, less apo B-89 ultimately reached the LDL fraction as compared with the apo B-I00. The greater selective losses ofapo B-89 from VLDL are also evident from the fact that with increasing particle density the ratio ofapo B-89 mass to apo B-l00 mass decreased (Table  II) . In Fig. 1 all rate constants as well as all transport rates are presented for one of the apo B-89/apo B-100 heterozygotes (subject 1, A), as well as for the apo B-40/apo B-89 compound heterozygote (subject 3, B). Note that in the apo B-89/apo B-I00 heterozygote, the rate constants ofall removal pathways are higher for apo B-89 than for apo B-100.
In the two apo B-89/apo B-100 heterozygotes it was possible to compare the metabolism of apo B-89 lipoproteins with that ofapo B-100 lipoproteins. Apo B-100 lipoproteins serving as "internal controls" for the metabolism of "normal" apo B containing particles. No such references were available for comparison in the compound heterozygote; however, the metabolic parameters for apo B-89 in this subject were similar to those estimated for apo B-89 in the apo B-89/apo B-100 heterozygotes (Tables III and IV) . Fig. 5 shows the tracer/tracee ratios for VLDL-, IDL-, and LDL-apo B-89 in the compound heterozygote (apo B-40/apo B-89). It can also be seen that in this subject there is good agreement between the multicompartmental fit and the observed data.
Discussion
This is the first report ofin vivo kinetics ofany truncated apolipoprotein in human subjects using stable isotopically labeled amino acids as endogenous tracers. Our studies show that in apo B-89/apo B-I00 heterozygotes, the low levels of apo B-89 relative to apo B-100 are due to increased FCR's oflipoproteins containing the truncated protein, while rates of production of apo B-89 are similar to those for apo B-100. By contrast, the FCR's ofthe truncated apolipoproteins are consistently higher in each lipoprotein fraction. The enhanced FCR's result from increased removal rates for each density class rather than increased conversion rates of lower to higher density lipoproteins, i.e., compared with apo B-100, a greater proportion of apo B-89 is irreversibly removed from the VLDL and IDL compartments before being converted. The FCR ofLDL is also higher for apo B-89 than for apo B-100 containing particles. The differences seen in the production rates between subjects 1 and 2 (father and son) may be related to the age ofthe subjects. Despite differences between father and son in absolute terms, the apo B-89/apo B-100 ratios for the kinetic parameters are similar. Apo B-40 metabolism was not studied in the compound heterozygote (3) because of the extremely low plasma levels of this apolipoprotein. These results are in accord with our earlier studies showing that apo B-89 containing LDL bound to cultured fibroblasts with greater affinity than apo B-100 containing LDL (4), and that the FCR of apo B-89 containing LDL was double that of apo B-100 containing control LDL in rabbits (6) . While these cell culture and animal studies demonstrated the different metabolic behavior of apo B-89 containing LDL, the metabolism of VLDL and IDL was not studied. The present in vivo studies demonstrate that not only LDL but all particles containing apo B-89 (VLDL, IDL, and LDL) were cleared from plasma at enhanced rates compared with apo B-100 containing particles. Based on our previous findings (4, 6) , these data are consistent with an enhanced removal of the lipoproteins via LDL receptors as the most likely mechanism. (19) . The FCRs for apo B-100 in our heterozygotes were similar to those obtained in our control subjects, suggesting that perhaps LDL-receptor activity is not upregulated in heterozygotes despite their low cholesterol levels. Production rates of apo B-100 for the controls ranged between 8.0 and 23.6 mg * kg-' -d-', and total production rates for apo B (apo B-89 plus apo B-100) in our heterozygotes fell at the lower end ofthis range. Thus, a reduced production rate oftotal apo B could be contributing to the hypobetalipoproteinemia seen in this kindred, but larger numbers of subjects need to be studied before this can be concluded with statistical certainty.
Two potential weaknesses of this study need to be discussed: (a) the appropriateness ofthe kinetic model; and (b) the accuracy ofthe estimated pool sizes. Leucine labeled with radioisotopes (24) or with stable isotopes (19, (25) (26) (27) have been used previously to study apolipoprotein metabolism. The model presented here is based on previously published models (15) (16) (17) (18) , and as demonstrated here, the model we developed for control subjects (19) can also describe the metabolism of our patients with only a slight modification of the model. We do, however, appreciate that this model may not fit tracer data ofother apo B truncations, particularly when the metabolic pathways of the truncated apo B are different from those of apo B-100 (e.g., in apo B-40 or apo B-54.8 [2] where LDL receptor recognition regions may be absent). Furthermore, it should be noted that recycling of the tracer might impair the calculation of kinetic parameters. As discussed elsewhere (19) , the problem of recycling impacts less upon the estimates of kinetic parameters of rapidly turning-over particles, i.e., VLDL, IDL, and more upon slowly turning-over particles such as LDL.
Pool sizes of apo B-89 and apo B-100 were estimated on the assumption that both proteins have the same chromogenicity.
While it has been shown that apo B48 differs in this respect from apo B-100 (23) , this is unknown for apo B-89. However, the similar molecular size of apo B-100 and apo B-89 makes significant differences unlikely. To the extent that estimated pool sizes are under-or overestimated, calculated production rates could also be in error. In fact, apo B production from the VLDL-IDL-LDL cascade combined with that from the shunt pathway could not account for all the apo B mass in the LDL fraction. As pointed out previously by us (19) and others (24) , this most likely reflects errors associated with the determination of pool sizes. While the percentage of apo B unaccounted for in the LDL fraction averaged around 7% in normolipidemic subjects (19) , this value was higher in subject 1 (Fig. 1) 
